SGLT2 Inhibitors Versus GLP-1 Receptor Agonists for Kidney Outcomes

01 Mar 20264 min read0 viewsJournal Feed

GIST

This comparative effectiveness research study examines whether kidney outcomes differ with sodium-glucose cotransporter-2 (SGLT2) inhibitor vs glucagon-like peptide-1 (GLP-1) receptor agonist treatment in individuals with type 2 diabetes.

Clinical Editorial

Summary

JAMA Internal Medicine published a clinical update in Research Highlights on 01 Mar 2026.

The item focuses on SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Community pharmacy-led diabetes management using continuous glucose monitoring for suboptimally controlled type 2 diabetes: A pilot feasibility study

Research Highlights • 22 May 2026

Endocrine NewsRelated by Conditiondiabetestype 2 diabetes

Pharma Friday – May 22, 2026

Research Highlights • 22 May 2026

Med News TodayRelated by Conditiondiabetestype 2 diabetes

How vitamin D in pregnancy could offer a head start for better cognitive health

Research Highlights • 22 May 2026

Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies

Research Highlights • 21 May 2026

Patient preferences and willingness-to-pay for AI-enabled blended type 2 diabetes care by digital experience and socioeconomic status: a discrete-choice experiment in China

Research Highlights • 20 May 2026

Medical nutrition therapy strategies for type 2 diabetes in Western and African contexts: a comparative scoping review protocol

Research Highlights • 20 May 2026

Feed Metadata

Source

JAMA Internal Medicine